Menu
Search
|

Menu

Close
X

Galapagos NV GLPG.AS (Amsterdam Stock Exchange)

90.74 EUR
-3.48 (-3.69%)
As of 11:35 AM EST
chart
Previous Close 94.22
Open 93.00
Volume 616,323
3m Avg Volume 431,178
Today’s High 93.96
Today’s Low 89.90
52 Week High 98.82
52 Week Low 61.88
Shares Outstanding (mil) 50.94
Market Capitalization (mil) 4,799.26
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 8 analysts

KEY STATS

Revenue (mm, EUR)
FY17
106
FY16
186
FY15
61
EPS (EUR)
FY17
-1.729
FY16
1.040
FY15
-3.214
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.59
Price to Sales (TTM)
vs sector
24.88
8.08
Price to Book (MRQ)
vs sector
4.62
5.24
Price to Cash Flow (TTM)
vs sector
--
25.98
Total Debt to Equity (MRQ)
vs sector
0.00
15.60
LT Debt to Equity (MRQ)
vs sector
0.00
12.18
Return on Investment (TTM)
vs sector
-3.82
13.67
Return on Equity (TTM)
vs sector
-4.57
15.40

EXECUTIVE LEADERSHIP

Rajesh Parekh
Non-Executive Chairman of the Board, Since 2004
Salary: --
Bonus: --
Onno van de Stolpe
Chief Executive Officer, Executive Director, Member of the Executive Committee, Since 1999
Salary: €394,543.00
Bonus: --
Bart Filius
Member of the Executive Committee, Chief Financial Officer, Chief Operating Officer, Since 2017
Salary: --
Bonus: --
Piet Wigerinck
Member of the Executive Committee, Chief Scientific Officer, Since 2012
Salary: --
Bonus: --
Elizabeth Goodwin
VP Corporate Communications & Investor Relations, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Generaal De Wittelaan 3
MALINES (MECHELEN)     2800

Phone: +3215.342900
Site: www.glpg.com

Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.

SPONSORED STORIES